*Sponsored
Market Crux Announces Coverage On Cosmos Health Inc. (NASDAQ:COSM) Starting This Morning—Friday, October 10, 2025
(COSM) Comes Backed By Several Potential Catalysts—But Here's
What We Can Tell You Tonight:
Limited Float: (COSM) Has Fewer Than 25M Shares Available, Which Could Create The Potential For Big Moves If Demand Begins Shifts.
Recent Momentum: (COSM) Moved Approximately 195% In Under Three Weeks And Is Now Showing 100% Bullish Signals On Barchart.
Digital Strategy: (COSM) Secured A $300M E-T-H Treasury Facility To Integrate Block-Chain Innovation Into Its Growth Framework.
Expanding Global Reach: (COSM) Is Extending Its Presence Across The U.S., Kuwait, And Oman Within A Nutraceuticals Market Projected To Exceed $1T.
AI-Driven Innovation: (COSM) Uses Its Proprietary Cloudscreen® AI Platform To Advance Research On Formulations For Obesity And Diabetes.
Pull Up (COSM) Before This Morning's Bell Rings…
October 10, 2025
Minutes Before The Bell | See Why We Have All Eyes On (COSM) Right Now Dear Reader, There's less than 10 minutes to go before the bell rings. After yesterday's profile made an approximate 63% move, we're now shifting gears to what's topping this morning's watchlist. The global nutraceuticals market is projected to exceed $1T within the next decade, reflecting sustained worldwide demand for products that promote long-term health and wellness. The term nutraceuticals broadly refers to products derived from food sources that provide additional health benefits beyond basic nutritional value. These products are developed to support overall well-being, help regulate physiological functions, and reduce the risk of chronic conditions, bridging the gap between nutrition and preventive healthcare. Amid this global wellness revolution, one little-known company — Cosmos Health Inc. (NASDAQ:COSM) — has quietly emerged as one of the most dynamic healthcare groups redefining the connection between science and everyday vitality.
Recently, (COSM) secured a financing facility of up to $300M to launch an E-T-H treasury strategy, reflecting the company's forward-thinking approach to innovation and digital transformation. But here's what many overlook: (COSM) has fewer than 25M shares available in its public float, according to MarketWatch. When floats are this small, there's the potential for big moves if demand begins to shift. In fact, (COSM) recently made an approximate 195% move in under three weeks — from $0.43 on July 18 to $1.28 by August 6.
And while it continues to trend quietly around the $1 range, (COSM) is currently flashing 100% bullish signals on Barchart's technical analysis tool, suggesting underlying strength that's drawing fresh attention to the story. Through its network of subsidiaries — SkyPharm, CosmoFarm, Cana Laboratories, Decahedron, and ZipDoctor — Cosmos Health maintains an expanding presence across Europe, North America, and the Middle East.
Its brands — Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept®, and C-Scrub® — are featured in pharmacies, retail stores, and major online platforms like Amazon and Holland & Barrett, now reaching over 2,000 locations in more than a dozen countries.
With in-house manufacturing through Cana Laboratories, certified by the European Medicines Agency (EMA), Cosmos produces pharmaceuticals, supplements, and cosmetics under strict quality standards. The company is also advancing AI-powered research aimed at developing new solutions for obesity, diabetes, and cancer — combining technology and science to strengthen its position within the global nutraceutical landscape. Recent Developments Driving Momentum
Expanding Horizons: Sky Premium Life® Enters Kuwait's
$1B+ Market
Cosmos Health (NASDAQ:COSM) expanded its Sky Premium Life® nutraceutical line into Kuwait through an exclusive agreement with Diyar United, a leading regional distributor. The deal includes an initial purchase order of over 65,000 units, targeting a market valued at $1.16B in 2024 and projected to grow to $1.68B by 2030. CEO Greg Siokas said the partnership underscores growing global trust in Sky Premium Life® as it strengthens the brand's international reach. Entering the World's Largest Nutraceutical Market:
U.S. Operations Commence
Shortly before the Kuwait announcement, Cosmos Health (NASDAQ:COSM) launched its Sky Premium Life® brand in the United States, entering the $164B U.S. nutraceutical market. Production takes place in FDA-registered and GMP-certified facilities, ensuring top-tier quality while supporting local operations. The debut product, Sky Premium Life NOOR Collagen, is projected to generate over $12M in annualized revenue with approximately 75% gross margins, setting the stage for additional product rollouts. Strengthening Its GCC Presence: Exclusive Distribution Deal in Oman
Cosmos Health (NASDAQ:COSM) continued its expansion across the $7B GCC nutraceutical market, signing an exclusive distribution agreement with Scientific Pharmacy LLC for Oman. The agreement includes an initial 42,000-unit order and leverages Scientific Pharmacy's established healthcare network. CEO Greg Siokas stated that this milestone "further strengthens our footprint across the GCC, underscoring both product quality and global demand." Digital Expansion: Launching a $300M E-T-H Treasury Strategy
In August 2025, Cosmos Health (NASDAQ:COSM) announced a financing facility of up to $300M to launch its digital asset treasury strategy, marking a major step in its broader digital transformation. The initiative includes the strategic accumulation and staking of E-T-H through institutional custody with BitGo Trust Company, aligning with Cosmos Health's vision to integrate block-chain into areas such as supply chain traceability, wellness incentives, and global consumer engagement. According to CEO Greg Siokas, the program provides both growth capital and long-term strategic positioning as the company explores additional yield-generating mechanisms from its ETH holdings. Innovation Engine: Biotech and AI-Powered R&D
Cosmos Health is developing a pipeline of novel pharmaceuticals and nutraceuticals, guided by its in-house Cloudscreen® AI platform, which uses 3D and 1D structural analytics to accelerate dr-ug repurposing and discovery. 
Key projects include: - CCX0722, an innovative obesity and weight management formulation with appetite suppression and energy metabolism properties. Patent applications were filed in December 2023, with clinical studies planned through 2025.
- CNS Cancer Program, involving dr-ug repurposing for glioblastoma and other brain cancers, with patent filings already submitted to EPO and WIPO.
- Anticancer Compounds targeting ovarian and prostate cancers, demonstrating high activity against resistant cell lines in preclinical data.
Cosmos plans to spin off its biotech R&D division into a standalone public company, unlocking value from its growing intellectual property portfolio and accelerating research partnerships across Europe. Building Momentum: Cosmos Health Targets $155M
in Annual Revenue by 2027
According to (COSM)'s corporate presentation, the company reported FY2024 estimated revenue of $55M+, with total assets of $65M and shareholder equity of $35M. The company maintains a solid balance sheet, a GMP manufacturing license, and a GDP-certified distribution network, supporting steady expansion and margin improvement. Looking ahead, (COSM) projects annual gross revenue of at least $155M and Adjusted EBITDA of $30M by 2027, driven by: - Expansion of CosmoFarm's wholesale network to $90M in annual revenue.
- Vertical integration via Cana Laboratories and new contract manufacturing agreements.
- Growing contributions from Sky Premium Life®, Mediterranation®, C-Sept®, and generic OTC portfolios.
- Cost efficiencies from group-wide optimization and technology adoption.
Leadership with Deep Sector Expertise
Under the leadership of CEO Greg Siokas, who has personally invested over $17M into the company, Cosmos Health is managed by an experienced team of executives and scientific advisors with backgrounds in pharma, M&A, and biotechnology. The company's governance framework emphasizes transparency, integrity, and execution discipline, supported by independent directors with proven capital markets and healthcare experience. A Company Positioned for Global Acceleration
Cosmos Health's steady progress — from AI-enabled dr-ug R&D to international distribution deals — highlights the company's unique blend of innovation, scalability, and execution. Its Sky Premium Life® brand continues to gain traction as a trusted name in high-quality wellness supplements, while its biotech initiatives signal the next stage of growth. With expanding operations across the U.S., Europe, and the Middle East — and the potential for a biotech spin-off — Cosmos Health (NASDAQ:COSM) represents a company entering a powerful new growth phase supported by science, strategy, and a vision for global impact. 7 Reasons Why (COSM) Is Topping Our Watchlist This Morning
—Friday, October 10, 2025 1. Limited Float: With fewer than 25M shares available, (COSM)'s small float could lead to the potential for big moves if demand begins to shift. 2. Recent Momentum: (COSM) recently saw an approximate 195% move in under three weeks, from $0.43 to $1.28, highlighting how quickly momentum can build around small-float names — and it's currently flashing 100% bullish signals on Barchart's technical analysis tool, suggesting continued underlying strength on the charts. 3. Digital Strategy: Through a $300M E-T-H treasury facility, (COSM) is integrating block-chain innovation into its long-term growth vision, blending traditional healthcare with next-generation digital assets. 4. Expanding Global Reach: Operating within a nutraceuticals market projected to exceed $1T within the next decade, (COSM) is extending its reach through exclusive partnerships in Kuwait and Oman and new operations across the U.S., positioning itself on three continents. 5. Strong Foundation: According to its investor presentation, (COSM) reported FY2024 revenue of $55M+ and projects at least $155M by 2027, supported by a solid balance sheet and expanding vertical integration. 6. AI-Driven Innovation: Using its proprietary Cloudscreen® AI platform, (COSM) is advancing research on novel formulations targeting major health conditions such as obesity and diabetes. 7. High-Growth Leadership Under CEO Greg Siokas, who has personally invested over $17M into the company, (COSM) continues to execute an aggressive expansion strategy backed by proven sector expertise. Pull Up (COSM) Before This Morning's Bell Rings…
With fewer than 25M shares in its float, (COSM) continues to stand out as a small-float healthcare name with growing global visibility. After an approximate 195% move in under three weeks, the momentum potential surrounding this company could catch the attention of technical watchers — especially with 100% bullish readings on Barchart's signal tool. Beyond the chart, (COSM) operates in a nutraceuticals market projected to exceed $1T within the next decade, expanding through partnerships in Kuwait, Oman, and the U.S., while its AI-powered R&D platform continues advancing next-generation formulations in wellness and health sciences. With a solid balance sheet, ambitious growth targets, and leadership that has personally backed the company with over $17M, (COSM) is beginning to capture attention for all the right reasons. We have all eyes on (COSM) this morning. Take a look at (COSM) while it's still early. Also, my next update could be out shortly after the bell rings, keep a lookout for it. Sincerely,
Gary Silver
Managing Editor,
Market Crux | 
